Dr. James M. Andry, MD

Medicare patients and services

Medicare patients, 2024

657

Services billed

2,716

Patients’ average age

71

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Payments from drug and device companies

In 2025, 9 companies reported 56 payments worth $16,218 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $403,545 in research payments for these studies, mostly to the institutions running them.

• A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Y…
  Jazz Pharmaceuticals Inc.
• A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
  Alkermes, Inc. · Recruiting · NCT06767683
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
  Alkermes, Inc. · Completed · NCT06555783
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
  Alkermes, Inc. · Completed · NCT06358950
• A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pres…
  Amgen Inc.
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
  Alkermes, Inc. · Active, not recruiting · NCT06843590
• A long-term extension study to evaluate the safety and tolerability of TAK-861 in participants with selected central hypersomnia conditions
  Takeda Pharmaceuticals U.S.A., Inc.
• An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV
  Jazz Pharmaceuticals Inc.
• A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure…
  Amgen Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Sleep Medicine clinicians in San Antonio

• Eleanor E. Avery, MD
• Nici E. Bothwell, MD
• Avie A. Grunspan, MD
• Karen Hentschel-franks, DO
• Shakil A. Khan, MD
• Victor Lam, M.D.
• Jose A. Palomares JR., MD
• Rafael M. Santiago, M.D.